Gapping up
In reaction to strong earnings/guidance: AMCO +37.8%, XGTI +9.6%, SLTD +9.5%, VRS +6.9%, GURE +6.9%, ITRN +5%, PBR +4.3%, ASTI +3.2%, KITE +1%, CLNT +1%
M&A news: ANN +21.9% (to be acquired by ascena retail group (ASNA) for price per share of ~$47.00), ASNA +9.8% (to acquire ANN for $47 per share), ALTR +6.5% (Intel (INTC) may resume takeover discussions with ALTR, according to NY Post), GTI +2.8% (Brookfield Asset Management (BAM) to commence tender offer for GTI common stock at $5.05/share), ENDP +0.5% (to acquire Par Pharmaceutical in a transaction valued at $8.05 bln)
Select metals/mining stocks trading higher: IGLD +3.4%, AUQ +1.6%, PAAS +1.3%, GG +1.3%, GOLD +1.2%
Other news: PSTI +8.6% (PLX cells were selected for European Medicines Agency's Adaptive Pathways Pilot Project), PVCT +8% (announces a 60 day extension of its MOU with the Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co), ITCI +4.8% (announces further analyses of the Phase 2 Clinical Trial of ITI-007), MNKD +3% (cont strength), URBN +2.3% (ANN peer), QSR +2% (announces repricing of first lien term loan facility), LVLT +1.8% (postive Barron's article), VGGL +1.7% (Exec Chairman/ CEO made an unsecured demand loan to the Company totaling $325k, bearing interest at the rate of 12% per annum), RIG +1.6% (approves dividend of $0.60 per share), AGIO +1.1% (AG-120 was granted FDA Fast Track Designation to treat Acute Myelogenous Leukemia with an IDH1 Mutation), TS +1% (restates carrying value of Usiminas investment), SGMO +1% (announces that new data from its ZFP Therapeutic programs in disease models of lysosomal storage disorders were presented last week which demonstrate proof of concept for its In Vivo protein replacement platform), CSIQ+0.9% (announced that Natixis will provide the company with up to C$53.5 Million in non-recourse, construction plus term financing)
Analyst comments: BIOD +10.6% (initiated with a Buy at ROTH Capital; tgt $5), PTBI +5.9% (initiated with a Buy at H.C. Wainwright; tgt $15), PFNX +5.5% (initiated with an Overweight at Barclays), ATEN +4.6% (upgraded to Overweight from Sector Weight at Pacific Crest), SSE +3.1% (upgraded to Buy from Hold at Jefferies), PENN +2.6% (upgraded to Buy from Neutral at Goldman), TNK +1.4% (initiated with a Overweight at JP Morgan), PDCE +1% (initiated with a Conviction Buy at Goldman), GPRO +0.7% (upgraded to Perform from Underperform at Oppenheimer
)
In reaction to strong earnings/guidance: AMCO +37.8%, XGTI +9.6%, SLTD +9.5%, VRS +6.9%, GURE +6.9%, ITRN +5%, PBR +4.3%, ASTI +3.2%, KITE +1%, CLNT +1%
M&A news: ANN +21.9% (to be acquired by ascena retail group (ASNA) for price per share of ~$47.00), ASNA +9.8% (to acquire ANN for $47 per share), ALTR +6.5% (Intel (INTC) may resume takeover discussions with ALTR, according to NY Post), GTI +2.8% (Brookfield Asset Management (BAM) to commence tender offer for GTI common stock at $5.05/share), ENDP +0.5% (to acquire Par Pharmaceutical in a transaction valued at $8.05 bln)
Select metals/mining stocks trading higher: IGLD +3.4%, AUQ +1.6%, PAAS +1.3%, GG +1.3%, GOLD +1.2%
Other news: PSTI +8.6% (PLX cells were selected for European Medicines Agency's Adaptive Pathways Pilot Project), PVCT +8% (announces a 60 day extension of its MOU with the Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co), ITCI +4.8% (announces further analyses of the Phase 2 Clinical Trial of ITI-007), MNKD +3% (cont strength), URBN +2.3% (ANN peer), QSR +2% (announces repricing of first lien term loan facility), LVLT +1.8% (postive Barron's article), VGGL +1.7% (Exec Chairman/ CEO made an unsecured demand loan to the Company totaling $325k, bearing interest at the rate of 12% per annum), RIG +1.6% (approves dividend of $0.60 per share), AGIO +1.1% (AG-120 was granted FDA Fast Track Designation to treat Acute Myelogenous Leukemia with an IDH1 Mutation), TS +1% (restates carrying value of Usiminas investment), SGMO +1% (announces that new data from its ZFP Therapeutic programs in disease models of lysosomal storage disorders were presented last week which demonstrate proof of concept for its In Vivo protein replacement platform), CSIQ+0.9% (announced that Natixis will provide the company with up to C$53.5 Million in non-recourse, construction plus term financing)
Analyst comments: BIOD +10.6% (initiated with a Buy at ROTH Capital; tgt $5), PTBI +5.9% (initiated with a Buy at H.C. Wainwright; tgt $15), PFNX +5.5% (initiated with an Overweight at Barclays), ATEN +4.6% (upgraded to Overweight from Sector Weight at Pacific Crest), SSE +3.1% (upgraded to Buy from Hold at Jefferies), PENN +2.6% (upgraded to Buy from Neutral at Goldman), TNK +1.4% (initiated with a Overweight at JP Morgan), PDCE +1% (initiated with a Conviction Buy at Goldman), GPRO +0.7% (upgraded to Perform from Underperform at Oppenheimer
)